By Chris Wack
Marker Therapeutics shares were up 19% to $2.98 after the company said the first patient has been treated in its Phase 1 trial investigating MT-601 for the treatment of patients with lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.
The stock closed Friday up 21%, and is now down just 2% in the past 12 months.
MT-601 is a multi-tumor-associated antigen-specific T cell product which Marker believes can be broadened to target six antigens for better and more durable responses by targeting more than one antigen to overcome antigen loss.
The primary objective of the exploratory Phase 1 clinical trial is to evaluate the optimum dose, safety and preliminary efficacy of MT-601 in patients with various lymphoma subtypes.
The first patient in the trial recently received MT-601 at the 200-million cell dose level, was monitored for 18 days, and showed no treatment-related adverse events, indicating that the therapy was well-tolerated.
Eight clinical sites across the U.S. are expected to cumulatively enroll up to 30 patients during the dose escalation phase.
Write to Chris Wack at chris.wack@wsj.com
Read the full article here